Chung Yoon Hee, Kim Daejin
Department of Anatomy, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
Department of Anatomy, Inje University College of Medicine, Busan, Republic of Korea
Anticancer Res. 2016 Jul;36(7):3383-94.
Phosphorylation of glycogen synthase kinase 3β (GSK3β) by phosphatidyl-inositide 3-kinase (PI3K)/protein kinase B (AKT) or inhibition of GSK3β with small-molecule inhibitor attenuates cell survival and proliferation and increases apoptosis in most cancer cell lines. In this study, we investigated the role of phosphorylated GSK3β activated by enhanced toll-like receptor 4 (TLR4) expression in drug-treated colon cancer cells as a model of post-chemotherapy cancer cells.
The effect of TLR4 stimulation on metastasis and apoptosis in drug-exposed colon cancer cells was determined by real-time polymerase chain reaction (PCR) and immunoblotting.
Despite the induction of apoptosis after treatment with oxaliplatin and 5-fluorouracil, lipopolysaccharide (LPS) stimulation via increased TLR4 in drug-treated cancer cells effectively inhibited apoptosis through up-regulation of expression of anti-apoptosis-related B-cell lymphoma 2 (BCL2) family proteins [X-linked inhibitor of apoptosis protein (XIAP), BCL2, and survivin] and drug-resistance proteins [multidrug-resistance protein 1 (MDR1), multidrug resistance-associated protein (MRP)1/2/3]. LPS-mediated signaling in drug-treated cancer cells elevated the expression of phosphorylated GSK3β, extracellular signal-regulated kinase (ERK), and the p65 subunit of nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB). Pharmacological inhibition of GSK3β (using SB216763) reduced phosphorylation of GSK3β, re-activated caspase-dependent apoptosis, and blocked the expression of cancer stem cell markers and invasive characteristics in LPS-stimulated drug-treated cells. In addition, the ERK-specific inhibitor, PD98059, triggered the apoptosis of TLR4-activated drug-exposed colon cancer cells, whereas there was no effect on the expression of epithelial-mesenchymal transition markers or GSK3β phosphorylation.
These results suggest that TLR4-induced GSK3β and ERK phosphorylation independently controls cancer cell survival and regulation of GSK3β and ERK after chemotherapy, making TLR4 a critical target for reducing drug resistance and metastasis in patients with colon cancer.
磷脂酰肌醇3激酶(PI3K)/蛋白激酶B(AKT)介导的糖原合酶激酶3β(GSK3β)磷酸化或用小分子抑制剂抑制GSK3β,可减弱大多数癌细胞系的细胞存活和增殖,并增加细胞凋亡。在本研究中,我们以化疗后的癌细胞为模型,研究了通过增强Toll样受体4(TLR4)表达激活的磷酸化GSK3β在药物处理的结肠癌细胞中的作用。
通过实时聚合酶链反应(PCR)和免疫印迹法测定TLR4刺激对药物处理的结肠癌细胞转移和凋亡的影响。
尽管用奥沙利铂和5-氟尿嘧啶处理后诱导了细胞凋亡,但药物处理的癌细胞中通过增加TLR4进行的脂多糖(LPS)刺激通过上调抗凋亡相关B细胞淋巴瘤2(BCL2)家族蛋白[X连锁凋亡抑制蛋白(XIAP)、BCL2和生存素]以及耐药蛋白[多药耐药蛋白1(MDR1)、多药耐药相关蛋白(MRP)1/2/3]的表达有效抑制了细胞凋亡。药物处理的癌细胞中LPS介导的信号传导提高了磷酸化GSK3β、细胞外信号调节激酶(ERK)和活化B细胞的核因子κ轻链增强子p65亚基(NF-κB)的表达。GSK3β的药理学抑制(使用SB216763)降低了GSK3β的磷酸化,重新激活了半胱天冬酶依赖性细胞凋亡,并阻断了LPS刺激的药物处理细胞中癌症干细胞标志物的表达和侵袭特性。此外,ERK特异性抑制剂PD98059引发了TLR4激活的药物处理结肠癌细胞的凋亡,而对上皮-间质转化标志物的表达或GSK3β磷酸化没有影响。
这些结果表明,TLR4诱导的GSK3β和ERK磷酸化独立控制癌细胞存活以及化疗后GSK3β和ERK的调节,使TLR4成为降低结肠癌患者耐药性和转移的关键靶点。